Welcome to our dedicated page for Viatris SEC filings (Ticker: VTRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
Viatris Inc. (VTRS) submitted a Form 144 reporting a proposed sale of 7,032 common shares with an aggregate market value of $72,044.59. The filing lists 1,165,872,127 shares outstanding and an approximate sale date of 09/11/2025 on NASDAQ. The securities were acquired on 03/04/2025 as restricted stock units that vested and are described as a compensatory payment. The broker/contact block lists an address for Viatris Inc. in Canonsburg, PA. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.
Insider grant reported: Viatris Inc. director and officer Andrew Enrietti received a grant of 75,401 restricted stock units (RSUs) on 08/15/2025. Each RSU represents the right to one share of Viatris common stock. The RSUs vest in three annual tranches: 25,134 shares vest on 08/15/2026, 25,133 on 08/15/2027, and 25,134 on 08/15/2028. Following the grant, Enrietti beneficially owns 75,401 shares reported as direct ownership. The Form 4 was signed by power of attorney on 08/19/2025 and lists Enrietti's title as Chief Administrative and Transformation Officer.
Viatris Inc. (VTRS) Form 3 reports that Andrew Enrietti, identified as an officer and director-level executive (Chief Administrative and Transformation Officer), beneficially owns 130,000 shares of common stock directly and holds multiple employee equity awards. The filing lists vested stock options exercisable between 2026 and 2030 covering 11,697 options and several restricted stock unit grants and dividend equivalent units totaling 99,237 underlying shares scheduled to vest on specified dates between 2026 and 2028.
Scott A. Smith, who serves as both Chief Executive Officer and a director of Viatris Inc. (VTRS), acquired 22,000 shares of the company’s common stock on 08/12/2025 at a weighted average price of $9.9882 per share. After the purchase, the reporting person directly beneficially owned 314,807 shares.
The filing notes the acquisition price represents a weighted average of purchases in a range from $9.68 to $10.12; the reporting person offered to provide detailed per-price quantities on request. This Form 4 discloses an insider purchase by the CEO, showing an increase in his direct holdings without any derivative transactions reported.
Viatris director David S. Simmons reported the acquisition of 22,820 restricted stock units (RSUs) with a transaction date of 08/11/2025. Each RSU represents the right to receive one share of Viatris common stock at a $0 conversion price, and the award is scheduled to vest on March 6, 2026, at which point the RSUs convert into common shares.
The Form 4 shows this as an insider equity award reported by a single reporting person and executed under a power of attorney. The filing documents an equity grant/vesting schedule rather than a sale or cash purchase.
Viatris Inc. (VTRS) Form 3 reports that David S. Simmons, identified as a Director, filed an initial beneficial ownership statement related to an event on 08/04/2025. The filing lists Mr. Simmons's address as 1000 Mylan Boulevard, Canonsburg, PA 15317. The form discloses no securities are beneficially owned by the reporting person. The document is signed on behalf of the reporting person by Kevin D. Macikowski, by power of attorney with a signature date of 08/13/2025. No derivative or non-derivative holdings, amendments, or additional relationships are reported beyond the director designation.
State Street Corporation reports beneficial ownership of 55,292,535 shares of Viatris common stock, representing 4.7% of the class. The filing shows shared voting power of 35,527,445 shares and shared dispositive power of 55,287,700 shares, with no sole voting or dispositive power reported.
The statement clarifies these holdings are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Multiple State Street Global Advisors affiliates are identified as the relevant subsidiaries involved in the holdings.